CN103142811A - Traditional Chinese medicine for treating primary osteoporosis - Google Patents
Traditional Chinese medicine for treating primary osteoporosis Download PDFInfo
- Publication number
- CN103142811A CN103142811A CN2013101046120A CN201310104612A CN103142811A CN 103142811 A CN103142811 A CN 103142811A CN 2013101046120 A CN2013101046120 A CN 2013101046120A CN 201310104612 A CN201310104612 A CN 201310104612A CN 103142811 A CN103142811 A CN 103142811A
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- kidney
- rhizoma
- osteoporosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a traditional Chinese medicine for treating primary osteoporosis. The technical scheme adopted by the invention is as follows: the traditional Chinese medicine is prepared from the following bulk drugs by weight: 15g of prepared rhizome of rehmannia, 15g of Chinese yam, 15g of morinda officinalis, 15g of cistanche salsa, 15g of eucommia bark, 15g of achyranthes, 15g of medlar, 15g of peach kernel, 15g of safflower, 15g of red paeonia, 15g of rhizoma ligustici wallichii, 15g of angelica, 10g of dragon blood, 10g of panax notoginseng, 15g of rhizoma drynariae, 15g of fructus psoraleae, 15g of lopseed, 9g of lopseed,15g of red sage root, 30g of Tuckahoe, 30g of radix astragali, 15g of costus root and 15g of dried orange peel. The medicine has the characteristics of safety in use, definite curative effect and convenience in long use.
Description
Technical field
The invention belongs to a kind of Chinese medicine composition, particularly a kind of the present invention of utilization treats the Chinese medicine of primary osteoporosis.
Background technology
Primary osteoporosis (Osteoporosis OP) is with advancing age and a kind of physiological degeneration that occurs, and sickness rate raises year by year.Medical circle compares deep research to OP in recent years, and achievement in research report is constantly arranged, and domesticly carries out the research of Chinese medicine prevention osteoporosis from the later stage eighties 20th century, obtain certain progress, but generally speaking, still lack a kind of safe and effectively, be convenient to the medicine of prolonged application.
Summary of the invention
Purpose of the present invention just is to provide a kind of use safety, determined curative effect, is convenient to the Chinese medicine of life-time service.
Its technical solution is as follows: described Chinese medicine is made by the pharmacodynamic raw materials of following components by weight percent:
Radix Rehmanniae Preparata 15g, Rhizoma Dioscoreae 15g, Radix Morindae Officinalis 15g, Herba Cistanches 15g, Cortex Eucommiae 15g, Radix Achyranthis Bidentatae 15g, Fructus Lycii 15g, Semen Persicae 15g, Flos Carthami 15g, Radix Paeoniae Rubra 15g, Rhizoma Chuanxiong 15g, Radix Angelicae Sinensis 15 g, Sanguis Draxonis 10g, Radix Notoginseng 10g, Rhizoma Drynariae 15 g, Fructus Psoraleae 15g, Herba speranskiae tuberculatae 15g, Radix Glycyrrhizae 9g, Radix Salviae Miltiorrhizae 15g, Radix Dipsaci 15g Poria 30g Radix Astragali 30g, Radix Aucklandiae 15g, Pericarpium Citri Reticulatae 15g.
Chinese medicine thinks that the kidney being the origin of congenital constitution, main store essential substances, main bone is given birth to marrow, and the growth promoter of bone, power and kidney essense prosperity and decline are in close relations, the bone marrow growth is active for the kidney essense abundance, skeleton obtains nourishing strong, otherwise deficiency of kidney-essence, the biochemical weary source of bone marrow, blood stored in the liver, essence and blood is changed mutually, and The liver and the kidney have a common source, liver governing tendons Shugu profit joint.Simultaneously, The spleen and stomach provide the material basis of the acquired, source of generating QI and blood, the nourishing of the congenital bad day after tomorrow, if taste void declines, kidney become homeless foster, deficiency of kidney-essence, spleen governing muscles extremity.Therefore primary disease is dirty relevant with kidney liver spleen three, controls and works as liver and kidney tonifying, replenishing QI to invigorate the spleen, life essence-filling, marrow-benefitting, bone and muscle strengthening.In the present invention, the Radix Rehmanniae Preparata sweet in the mouth is warm in nature, returns the Liver and kidney warp, nourishing YIN and supplementing blood, and beneficial essence is filled out marrow; The Rhizoma Dioscoreae sweet in the mouth is warm in nature, returns the Liver and kidney warp, liver and kidney tonifying,, two medicines share with nourishing kidney yin, and bone and muscle strengthening is monarch drug.The Cortex Eucommiae, Radix Achyranthis Bidentatae, Fructus Lycii, Radix Dipsaci invigorating the liver and kidney, benefiting essence-blood, strong waist knee joint, the Radix Dipsaci of curing the wound is ministerial drug altogether.Assistant is with the Radix Astragali, Rhizoma Atractylodis Macrocephalae replenishing QI to invigorate the spleen, Radix Angelicae Sinensis blood circulation promoting and enriching, Scorpio promoting blood circulation to remove obstruction in the collateral, the Radix Aucklandiae, Pericarpium Citri Reticulatae regulating QI to relieve pain.Fructus Psoraleae has the effect of warming the kidney to activate YANG, improving inspiration by invigorating kidney-QI, antidiarrheal.Herba speranskiae tuberculatae has promoting blood circulation and stopping pain, the effect of the dampness that relieves internal heat.Radix Salviae Miltiorrhizae has promoting blood circulation to remove blood stasis, the effect of sedation-analgesia.But Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription.All medicines share, and play altogether invigorating kidney, promoting blood circulation, bone and muscle strengthening, replenishing QI to invigorate the spleen, the merit of promoting blood circulation to remove obstruction in the collateral.The selected main medicine of the present invention confirms all to have the body of adjusting mineral metabolism through pharmacological research, reduce osteoporosis and occur, impel osteoporosis improve or recover, suppress or correct going down of hypothalamus-pituitary system function, improve the endocrine disturbance, delay the effect of body aging process.In sum, we comprehensively always treat the experience of primary osteoporosis, and a large amount of documents thinks that the pathogen and pathology of tcm of O P is relevant with the spleen deficiency and blood stasis of suffering from a deficiency of the kidney, and are especially particularly close with the relation of suffering from a deficiency of the kidney, and the bone density of suffering from a deficiency of the kidney, bone mineral content are closely related.the kidney generating marrow and dominating bone, suffering from a deficiency of the kidney is osteoporotic main cause, treatment should be take the kidney invigorating as main, function of immune system can be corrected in the kidney invigorating low, recover the functional activity of Hypothalamus-pituitary-target organ, promote the deposition of bone calcium, have simultaneously the bone resorption of inhibition and increase and accelerate osteoplastic effect, not only can delay bone loss, even can increase the bone amount, Chinese medicine is compared with Western medicine, has curative effect high, not only promote sclerotin to recover, and can carry high bone mass, toxic and side effects is little, almost there is no untoward reaction, can prolonged application, effect comprehensively, can reconcile endocrine, the functional status of a plurality of systems such as immunity, play under the advantage of Comprehensive Treatment effect, by clinical Syndrome Differentiation of Traditional Chinese Medicine, because card is controlled suitable, confirmed that the Chinese medicine primary osteoporosis is evident in efficacy, it not only can be used for the treatment of in the recent period, can also the generation that be used for the prevention primary osteoporosis at a specified future date.
The present invention can have following preparation method: at first take each pharmacodynamic raw materials by above-mentioned weight ratio, all medicines except Radix Notoginseng, Sanguis Draxonis are put into marmite, and soaked three hours with the 2000ml pure water; simmer in water and boil 100 minutes, add and use intense fire after Radix Notoginseng, Sanguis Draxonis instead and decoct and ceased fire in 10 minutes, filter medicinal residues and get final product; wherein the Radix Aucklandiae is given birth to and is used; the close moxibustion use of the Radix Astragali, Rhizoma Chuanxiong wine use, Pericarpium Citri Reticulatae is given birth to and is used; Radix Achyranthis Bidentatae wine is fried; Radix Dipsaci, Cortex Eucommiae saline are fried use, and Rhizoma Dioscoreae is fried use, use after Radix Notoginseng, Sanguis Draxonis are pulverized.
The applicant utilizes the present invention to treat primary osteoporosis 560 examples, obtains satisfactory effect.Result is as follows.1 clinical data 1.1 diagnostic criterias are pressed the standard that osteoporosis committee of Aged in China association formulates and are carried out, and the T<2SD at any position is diagnosed as osteoporosis.Chinese medical discrimination is by following standard.1. deficiency of the kidney yin type: aching pain in waist and back, lower limb wither soft unable, vertigo and tinnitus, and the dysphoria with smothery sensation dry pharynx, hectic fever night sweat, seminal emission, Mental fatigue is forgetful, the loss of hairs luxated tooth, the red tongue tongue is few, thready and rapid pulse or thin and delicate.2. kidney yang deficiency syndrome: the spinal column cold type of pain, soreness of the waist and knees, aversion to cold and cold limbs, numb hand and foot, tired, the complexion white light is white, impotence and premature ejaculation, frequent micturition or nocturia frequency, pale tongue with white fur, deep-thready pulse or unable.3. deficiency of both YIN and YANG type: doublely see both symptoms.1.2 inclusive criteria meets above-mentioned Chinese and western medicine diagnostic criteria, age 60-80 year.1.3 1. exclusion standard does not meet diagnosis of osteoporosis standard and inclusive criteria; 2. secondary osteoporosis and idiopathic osteoporosis disease.1.4 case-data is taken in patient's 560 examples that meet above-mentioned standard, male 210 examples, female's 350 examples altogether.Age 60-80 year, average 65 ± 5 years old.Course of disease 2-10, average 7 years.Deficiency of the kidney yin type, each 200 examples of kidney yang deficiency syndrome, deficiency of both YIN and YANG type 160 examples.2 Therapeutic Method 2.1 side's medicines form Radix Rehmanniae Preparata 15g, Rhizoma Dioscoreae 15g, Radix Morindae Officinalis 15g, Herba Cistanches 15g, Cortex Eucommiae 15g, Radix Achyranthis Bidentatae 15g, Fructus Lycii 15g, Semen Persicae 15g, Flos Carthami 15g, Radix Paeoniae Rubra 15g, Rhizoma Chuanxiong 15g, Radix Angelicae Sinensis 15 g, Sanguis Draxonis 10g, Radix Notoginseng 10g, Rhizoma Drynariae 15 g, Fructus Psoraleae 15g, Herba speranskiae tuberculatae 15g, Radix Glycyrrhizae 9g, Radix Salviae Miltiorrhizae 15g, Radix Dipsaci 15g Poria 30g Radix Astragali 30g, Radix Aucklandiae 15g, Pericarpium Citri Reticulatae 15g.2.2 all cases of therapeutic scheme are all taken the present invention, day potion divides sooner or later and takes for twice.All take 2 months as 1 course for the treatment of, totally 3 courses for the treatment of, all withdraw other medicines relevant to primary disease during medication.Carry out routine blood test, routine urinalysis, hepatic and renal function inspection observation medication side effect before and after 3 observational technique 3.1 safety observation treatments.3.2 observation index and method be clinical efficacy 1.: observe 560 examples in the recent period and the variation of symptom and sign at a specified future date.2. BMD: adopt the U.S. QDR5400A of Hologic company borne densitometers to measure femoral neck BMD, survey 1 time after 3 courses for the treatment of.3. BGP: select the RIA method to measure.4. PYD: select the ELISA method to measure.4 result 4.1 clinical efficacies as shown in table 1,2, reach after various treatment after drug withdrawal half a year with treatment before Clinical efficacy comparison, significant difference (P<0.05) is arranged; After treatment with drug withdrawal half a year after comparison, there was no significant difference (P〉0.05).Table 1 is (before and after treatment) Clinical efficacy comparison table in the recent period
The disease type | Number of cases | Produce effects | Effectively | Total effective rate (%) |
The deficiency of the kidney yin type | 200 | 197 | 3 | 100 |
Kidney yang deficiency syndrome | 200 | 197 | 3 | 100 |
The deficiency of both YIN and YANG type | 160 | 158 | 2 | 100 |
Table 2 long term (drug withdrawal half a year after) Clinical efficacy comparison table
The disease type | Number of cases | Produce effects | Effectively | Total effective rate (%) |
The deficiency of the kidney yin type | 200 | 193 | 7 | 100 |
Kidney yang deficiency syndrome | 200 | 195 | 5 | 100 |
The deficiency of both YIN and YANG type | 160 | 156 | 4 | 100 |
5 acute toxicity testings of the present invention
Experiment material
(1), animal: Kunming mouse, body weight 18-22g, male and female half and half.
(2), experimental technique: first adopt the HornShi method to measure LD
50, dead and any poisoning symptom do not appear in maximum concentration 10000mg/kg animal as a result.Transform maximum tolerated dose into.Divide 2 groups at random with mice, according to maximal dose (the suitable crude drug 3g of every ml) and maximum gastric capacity 0.4ml/10g in the morning 8:00,12:00,16:00, give Bushen Huoxue Fang for three times on the one gavages of mice, accumulative total administration 30g/kg, the toxic reaction of close observation mice and death condition after administration, Continuous Observation 7 days.
Result: press maximum concentration and heap(ed) capacity to mouse stomach, be equivalent to 280 times of quantity, in 20 mices 7 days, none is dead and poisoning, the administration animal is without extremely, each internal organs no abnormality seen after dissecting according to the Wrightization rule, proves that oral medicine is safe.
6 conclusion osteoporosis are to reduce with the bone amount, and the osseous tissue microstructure deteriorates to feature, thereby cause a kind of general osteopathia that fragility increases and fracture risk increases of bone.The pathogeny of osteoporosis is complicated, comes from the endocrine disturbance, and is bad as the microcosmic pathomechanism take the biological behaviour imbalance between osteoblast and osteoclast, calcium and phosphorus metabolism disorder, local bone tissue biomechanics load imbalance, electrical signal conduction.In recent years, Chinese scholars compares deep research to it, and the achievement in research report is constantly arranged.
The research of doctor trained in Western medicine aspect is mainly reflected in the following aspects: 1. people's pituitary adrenal axis angle is inquired into I type primary osteoporosis; 2. the effect of calcitonin to bone density and bone strength; 3. the relation of estrogen receptor (ER) gene pleiomorphism bone density (BMD), bone metabolism; 4. the impact of estrogen replacement therapy (ERT) on nervous tissue's Protein S-100, gap junction protein CX43 expression in removal ovary osteoporosis (OVX-OP) rat adenohypophysis folliculus profiling (FS) cell; 5. BMP gene therapy; 6. the Progress in diagnosis of senile osteoporosis; 7. dependency of osteoporosis and degenerative osteoarthritis etc.The traditional Chinese medical science thinks that according to its pathological characters this disease belongs to the categories such as " bone fistula ", " bone is withered ", " bone exhaustion ", " rheumatism involving the bone ".The biochemical weary source of deficiency of kidney-essence, bone marrow is the basic reason that causes osteoporosis.In treatment, the combination of Chinese and Western medicine or treatment by Chinese herbs have obtained effect preferably.Clinical research as application kidney tonifying, essence replenishing method control postmenopausal osteoporosiss such as Shi Qi; Liu Jianmin etc. use " tonify deficiency blood stasis dispelling " Chinese patent medicine Huoluogukang pills treatment primary osteoporosis; Han Mailu etc. are drug application, motion, food and pulse electromagnetic field Comprehensive Treatment primary osteoporosis; Punishment Hai Qing etc. use the Chinese medicine prevention diabetic osteoporosis.Although former osteoporosis of integrative therapy obtained certain achievement, all long-term existence is following not enough: OP be there is no the Chinese herb decoction treatment of clear and definite system; There is no unified diagnosis and treatment standard; Be unfavorable for clinical judgment, in the application of Chinese medicine, lack modern pharmacological research, lack medication with strong points, that target is single-minded.We improve above-mentioned deficiency for its pathogeny, utilize Coryza Treated by Syndrome Differentiation primary osteoporosis of the present invention, and its principle is as follows.Chinese medicine thinks that the kidney being the origin of congenital constitution, main store essential substances, main bone is given birth to marrow, and the growth promoter of bone, power and kidney essense prosperity and decline are in close relations, the bone marrow growth is active for the kidney essense abundance, skeleton obtains nourishing strong, otherwise deficiency of kidney-essence, the biochemical weary source of bone marrow, blood stored in the liver, essence and blood is changed mutually, and The liver and the kidney have a common source, liver governing tendons Shugu profit joint.Simultaneously, The spleen and stomach provide the material basis of the acquired, source of generating QI and blood, the nourishing of the congenital bad day after tomorrow, if taste void declines, kidney become homeless foster, deficiency of kidney-essence, spleen governing muscles extremity.Therefore primary disease is dirty relevant with kidney liver spleen three, controls and works as liver and kidney tonifying, replenishing QI to invigorate the spleen, life essence-filling, marrow-benefitting, bone and muscle strengthening.
In sum, the present invention compares with medicine in the past, has curative effect high, not only promote sclerotin to recover, and can carry high bone mass, toxic and side effects is little, almost there is no untoward reaction, can prolonged application, effect comprehensively, can reconcile the functional status of a plurality of systems such as endocrine, immunity, play under the advantage of Comprehensive Treatment effect, by clinical Syndrome Differentiation of Traditional Chinese Medicine, because card is controlled suitable, confirmed that the Chinese medicine primary osteoporosis is evident in efficacy, it not only can be used for the treatment of in the recent period, can also the generation that be used for the prevention primary osteoporosis at a specified future date.
Claims (2)
1. Chinese medicine for the treatment of primary osteoporosis, it is characterized in that, described Chinese medicine is made by the pharmacodynamic raw materials of following components by weight percent: Radix Rehmanniae Preparata 15g, Rhizoma Dioscoreae 15g, Radix Morindae Officinalis 15g, Herba Cistanches 15g, Cortex Eucommiae 15g, Radix Achyranthis Bidentatae 15g, Fructus Lycii 15g, Semen Persicae 15g, Flos Carthami 15g, Radix Paeoniae Rubra 15g, Rhizoma Chuanxiong 15g, Radix Angelicae Sinensis 15 g, Sanguis Draxonis 10g, Radix Notoginseng 10g, Rhizoma Drynariae 15 g, Fructus Psoraleae 15g, Herba speranskiae tuberculatae 15g, Radix Glycyrrhizae 9g, Radix Salviae Miltiorrhizae 15g, Radix Dipsaci 15g Poria 30g Radix Astragali 30g, Radix Aucklandiae 15g, Pericarpium Citri Reticulatae 15g.
2. one kind prepares a kind of preparation method for the treatment of the Chinese medicine of primary osteoporosis as claimed in claim 1, it is characterized in that: at first take each pharmacodynamic raw materials by above-mentioned weight ratio, all medicines except Radix Notoginseng, Sanguis Draxonis are put into marmite, and soaked three hours with the 2000ml pure water, simmer in water and boil 100 minutes, use intense fire decoction truce in 10 minutes instead after adding Radix Notoginseng, Sanguis Draxonis, filter medicinal residues and get final product; Wherein the Radix Aucklandiae is given birth to use, the close moxibustion use of the Radix Astragali, and Rhizoma Chuanxiong wine use, Pericarpium Citri Reticulatae is given birth to use, and Radix Achyranthis Bidentatae wine is fried, and Radix Dipsaci, Cortex Eucommiae saline are fried use, and Rhizoma Dioscoreae is fried use, uses after Radix Notoginseng, Sanguis Draxonis are pulverized.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013101046120A CN103142811A (en) | 2013-03-29 | 2013-03-29 | Traditional Chinese medicine for treating primary osteoporosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013101046120A CN103142811A (en) | 2013-03-29 | 2013-03-29 | Traditional Chinese medicine for treating primary osteoporosis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103142811A true CN103142811A (en) | 2013-06-12 |
Family
ID=48541320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013101046120A Pending CN103142811A (en) | 2013-03-29 | 2013-03-29 | Traditional Chinese medicine for treating primary osteoporosis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103142811A (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104027476A (en) * | 2014-07-01 | 2014-09-10 | 华梅 | Traditional Chinese medicine white spirit for treating osteoporosis and preparation method thereof |
CN104027534A (en) * | 2014-07-01 | 2014-09-10 | 华梅 | Traditional Chinese medicine white spirit for treating ischemic necrosis of femoral head and preparation method thereof |
CN104688932A (en) * | 2015-04-08 | 2015-06-10 | 房经武 | Traditional Chinese medicine preparation for postmenopausal osteoporosis and preparation method |
CN104826003A (en) * | 2015-04-23 | 2015-08-12 | 孙刚 | Traditional Chinese medicine granules for treating osteoporosis and preparation method thereof |
CN105477504A (en) * | 2016-01-15 | 2016-04-13 | 俞天阳 | Medicine used for treating primary osteoporosis |
CN105535166A (en) * | 2016-01-26 | 2016-05-04 | 马同英 | Nursing liquid medicine taken after fracture and preparation method thereof |
CN105943809A (en) * | 2016-06-18 | 2016-09-21 | 三穗县人民医院 | Traditional Chinese medicine pill for treating osteoporosis |
EP3117834A1 (en) * | 2015-07-14 | 2017-01-18 | Infinitus (China) Company Ltd. | A bone and joint protection composition and use thereof |
CN107320683A (en) * | 2017-06-30 | 2017-11-07 | 范闯法 | A kind of Chinese medicine for treating caput femoris necrosis |
CN110934941A (en) * | 2019-12-21 | 2020-03-31 | 邹祥发 | Traditional Chinese medicine composition for treating osteoporosis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1106674A (en) * | 1994-10-13 | 1995-08-16 | 汪志伟 | Traditional Chinese medicine for curing paralysis |
CN102078480A (en) * | 2010-06-02 | 2011-06-01 | 成进学 | Nano element traditional Chinese medicine negative ion far infrared electromagnetic wave-resistant life prolonging medicinal liquor |
-
2013
- 2013-03-29 CN CN2013101046120A patent/CN103142811A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1106674A (en) * | 1994-10-13 | 1995-08-16 | 汪志伟 | Traditional Chinese medicine for curing paralysis |
CN102078480A (en) * | 2010-06-02 | 2011-06-01 | 成进学 | Nano element traditional Chinese medicine negative ion far infrared electromagnetic wave-resistant life prolonging medicinal liquor |
Non-Patent Citations (4)
Title |
---|
卢心宇: "辨证治疗老年性骨质疏松症", 《福建中医学院学报》, vol. 4, no. 01, 1 March 1994 (1994-03-01) * |
张春玲等: "骨质疏松症的治疗经验与体会", 《中国中医药信息杂志》, vol. 9, no. 03, 31 March 2002 (2002-03-31) * |
承彬等: "补肾活血方药治疗绝经后骨质疏松症研究进展", 《吉林中医药》, vol. 26, no. 09, 30 September 2006 (2006-09-30) * |
温晶等: "《补肾活血方治疗原发性骨质疏松症的临床研究》", 《医药前沿》, no. 6, 29 February 2012 (2012-02-29) * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104027476A (en) * | 2014-07-01 | 2014-09-10 | 华梅 | Traditional Chinese medicine white spirit for treating osteoporosis and preparation method thereof |
CN104027534A (en) * | 2014-07-01 | 2014-09-10 | 华梅 | Traditional Chinese medicine white spirit for treating ischemic necrosis of femoral head and preparation method thereof |
CN104688932A (en) * | 2015-04-08 | 2015-06-10 | 房经武 | Traditional Chinese medicine preparation for postmenopausal osteoporosis and preparation method |
CN104826003A (en) * | 2015-04-23 | 2015-08-12 | 孙刚 | Traditional Chinese medicine granules for treating osteoporosis and preparation method thereof |
EP3117834A1 (en) * | 2015-07-14 | 2017-01-18 | Infinitus (China) Company Ltd. | A bone and joint protection composition and use thereof |
CN105477504A (en) * | 2016-01-15 | 2016-04-13 | 俞天阳 | Medicine used for treating primary osteoporosis |
CN105535166A (en) * | 2016-01-26 | 2016-05-04 | 马同英 | Nursing liquid medicine taken after fracture and preparation method thereof |
CN105943809A (en) * | 2016-06-18 | 2016-09-21 | 三穗县人民医院 | Traditional Chinese medicine pill for treating osteoporosis |
CN107320683A (en) * | 2017-06-30 | 2017-11-07 | 范闯法 | A kind of Chinese medicine for treating caput femoris necrosis |
CN110934941A (en) * | 2019-12-21 | 2020-03-31 | 邹祥发 | Traditional Chinese medicine composition for treating osteoporosis |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103142811A (en) | Traditional Chinese medicine for treating primary osteoporosis | |
CN100402066C (en) | Plaster for treating rheumatism and osteoarthrosis | |
CN102526326B (en) | Traditional Chinese medicine for treating postmenopausal osteoporosis and preparation method thereof | |
CN103330805A (en) | Traditional Chinese medicine composition for treating menorrhagia | |
CN102512632A (en) | Chinese herbal composition for treating abnormal menstruation | |
CN101095768B (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
CN1823972A (en) | Medicine for treating celevical vertebra disease | |
CN102988616B (en) | Chinese medicinal composition for treating anemia | |
CN100418553C (en) | Preparation for treating osteoporosis and preparation method thereof | |
CN101940674A (en) | Chinese medicament for treating diabetic peripheral neuropathy | |
CN104840577A (en) | Traditional Chinese medicine for treating pantalgia after childbirth | |
CN101024010A (en) | Chinese medicine for invigorating Qi and tonifying kidney, and anti-sanility | |
CN103550688A (en) | Traditional Chinese medicine (TCM) composition for treating palpitation | |
CN103585414B (en) | Pharmaceutical composition for treating sciatica and osteoporosis | |
CN102512560A (en) | Traditional Chinese medicinal composition for treating arthromyodynia | |
CN101961467A (en) | Medicine for treating knee osteoarthritis and preparation method and application thereof | |
CN1075727C (en) | Shentong capsule and preparing method thereof | |
CN105250809A (en) | Traditional Chinese medicine composition for treating dermatomyositis | |
CN101703660B (en) | Anti-aging medicament | |
CN104758439A (en) | Traditional Chinese medicine composition for treating thoracic obstruction | |
CN103860905A (en) | Traditional Chinese medicine preparation for treating osteoporosis | |
CN100363036C (en) | Chinese medicine composition for treating diabets and preparing method | |
CN102552766B (en) | Traditional Chinese medicine used for treating postmenopausal osteoporosis, preparation method thereof, and administration method thereof | |
CN103800833A (en) | Traditional Chinese medicine composition for treating deficiency of liver-yin and kidney-yin | |
CN103690925A (en) | Traditional Chinese medicinal composition for treating amenorrhea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130612 |